Herpes Zoster and Postherpetic Neuralgia: Prevention and Management

AARON SAGUIL, MD, MPH; SHAWN KANE, MD; and MICHAEL MERCADO, MD, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland
REBECCA LAUTERS, MD, Nellis Family Medicine Residency, Mike O’Callaghan Federal Medical Center, Nellis Air Force Base, Nevada

Herpes zoster, or shingles, is caused by reactivation of varicella zoster virus, which causes chickenpox. There are an estimated 1 million cases in the United States annually, with an individual lifetime risk of 30%. Patients with conditions that decrease cell-mediated immunity are 20 to 100 times more likely to develop herpes zoster. Patients may present with malaise, headache, low-grade fever, and abnormal skin sensations for two to three days before the classic maculopapular rash appears. The rash is usually unilateral, confined to a single dermatome, and typically progresses to clear vesicles that become cloudy and crust over in seven to 10 days. Herpes zoster can be treated with acyclovir, valacyclovir, or famciclovir, ideally within 72 hours of the development of the rash. Postherpetic neuralgia is the most common complication, occurring in about one in five patients. It is defined as pain in a dermatomal distribution sustained for at least 90 days after acute herpes zoster. Treatment is focused on symptom control and includes topical lidocaine or capsaicin and oral gabapentin, pregabalin, or tricyclic antidepressants. The varicella zoster virus vaccine decreases the incidence of herpes zoster and is approved for adults 50 years and older. The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices recommends this vaccine for adults 60 years and older, except for certain immunosuppressed patients. (Am Fam Physician. 2017;96(10):656-663. Copyright © 2017 American Academy of Family Physicians.)

Herpes zoster, or shingles, is caused by reactivation of varicella zoster virus (VZV), which causes chickenpox. It presents as painful blistering and occurs when VZV cell-mediated immunity wanes with age or immunocompromise. Postherpetic neuralgia; and visual, neurologic, or visceral complications. Erythematous, maculopapular rash appears. The rash is usually unilateral, confined to a single dermatome, and typically progresses to clear vesicles that become cloudy and crust over in seven to 10 days. Herpes zoster can be treated with acyclovir, valacyclovir, or famciclovir, ideally within 72 hours of the development of the rash. Postherpetic neuralgia is the most common complication, occurring in about one in five patients. It is defined as pain in a dermatomal distribution sustained for at least 90 days after acute herpes zoster. Treatment is focused on symptom control and includes topical lidocaine or capsaicin and oral gabapentin, pregabalin, or tricyclic antidepressants. The varicella zoster virus vaccine decreases the incidence of herpes zoster and is approved for adults 50 years and older. The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices recommends this vaccine for adults 60 years and older, except for certain immunosuppressed patients. (Am Fam Physician. 2017;96(10):656-663. Copyright © 2017 American Academy of Family Physicians.)

Epidemiology
An estimated 1 million cases of herpes zoster occur in the United States annually, with an individual lifetime risk of 30%. About 2% to 3% of patients with this condition are hospitalized each year, with costs ranging from $1 billion to $2 billion annually. In a typical family practice with 1,500 patients, three to five cases of herpes zoster can be expected each year. Almost all adults in the United States have been exposed to VZV. The incidence of herpes zoster ranges from one to three cases per 1,000 person-years in those younger than 50 years. Age is a major risk factor; T lymphocyte-specific immunity to the virus wanes over time, and more than one-half of unvaccinated patients 85 years and older will be affected. Women are at increased risk, whereas blacks are at decreased risk. Patients with conditions that decrease cell-mediated immunity (e.g., lymphoproliferative disorders, immunosuppressive drug use, human immunodeficiency virus seropositivity) are at 20 to 100 times greater risk compared with age-matched controls.

Clinical Presentation
As the initial VZV infection resolves, viral particles travel to cranial and dorsal root ganglia, where they are shielded from blood antibodies. The virus remains latent and may reactivate as cell-mediated immunity wanes. Not all of the contributing factors are understood, but under the right conditions, the virus replicates, causing a nonspecific prodrome with malaise, headache, fever, or abnormal skin sensations (e.g., itching, burning, pain). The classic rash typically
appears after two to three days, with new lesions appearing over three to five days (Figure 1). Usually affecting a single, unilateral dermatome, maculopapular lesions appear proximally to distally, progressing to clear vesicles that become cloudy and eventually crust over in seven to 10 days. Lesions usually heal two to four weeks after onset, but scarring and pigmentation changes are common.

Most lesions develop between dermatomes T1 and L2, although the ophthalmic (first) division of the trigeminal nerve is affected in 15% of cases. Adjacent dermatomes are affected in 20% of cases, and lesions occasionally cross the midline, especially on the back.

**Diagnosis**

The diagnosis of herpes zoster is typically clinical. Although herpes zoster is difficult to identify during the prodrome, the appearance of the typical exanthem aids in diagnosis. Testing is typically not needed, but it may be considered in patients with recurring lesions that are suspicious for herpes simplex, or in those with suspected zoster sine herpete, in which the virus causes pain without lesions. Testing may also be considered in atypical presentations, such as the widely disseminated lesions that may occur in immunocompromised patients. Testing is also helpful in differentiating herpes zoster from other vesicular dermatoses, such as contact dermatitis and dermatitis herpetiformis. Polymerase chain reaction testing of vesicle or other body fluids is preferred because of its high sensitivity and specificity (95% and 100%, respectively) and short turnaround (typically one day).

**Management of Acute Herpes Zoster**

Herpes zoster is treated with oral guanosine analogues (Table 1). These medications target VZV by relying on viral kinases for phosphorylation, which promotes incorporation into viral DNA, thus disrupting replication. Acyclovir is less expensive but has lower bioavailability and must be taken five times per day. Valacyclovir (Valtrex), a prodrug of acyclovir, is taken three times per day, as is famciclovir. Acyclovir is the only antiviral medication approved for the treatment of herpes zoster in children. Patients with severe disease, especially those with
immunocompromise, should be treated with intravenous acyclovir. Although treatment of herpes zoster ideally should be started within 72 hours of the appearance of the rash, treatment is still warranted outside the 72-hour window if new skin lesions are developing or if ophthalmic or neurologic complications are present.

<table>
<thead>
<tr>
<th>Table 1. Pharmacologic Therapies for Acute Herpes Zoster</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agent</td>
</tr>
<tr>
<td>-------</td>
</tr>
<tr>
<td><strong>Antivirals</strong></td>
</tr>
<tr>
<td>Acyclovir</td>
</tr>
<tr>
<td>Famciclovir</td>
</tr>
<tr>
<td>Valacyclovir (Valtrex)</td>
</tr>
<tr>
<td><strong>Adjunctive therapy</strong></td>
</tr>
<tr>
<td>Corticosteroids (e.g., prednisone, prednisolone)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Analgesics</strong></td>
</tr>
<tr>
<td>Acetaminophen</td>
</tr>
<tr>
<td>Nonsteroidal anti-inflammatory drugs (e.g., ibuprofen)</td>
</tr>
</tbody>
</table>


Information from references 1, and 10 through 13.
Acyclovir decreases the time during which new lesions occur by 12 hours and the time to full crusting by two days, while decreasing pain severity. Valacyclovir and famciclovir have similar effects. The use of antiviral medications does not reduce the incidence of postherpetic neuralgia.

Glucocorticoids are an adjunct to antiviral therapy; they reduce acute pain and promote early healing. Glucocorticoids do not reduce the incidence of postherpetic neuralgia and should not be used without antivirals. Treatment of acute pain depends on its severity and impact. Mild to moderate pain may be controlled with acetaminophen or nonsteroidal anti-inflammatory agents. Severe cases may require opioids, although such prescriptions should follow established guidelines. Anticonvulsants, tricyclic antidepressants, or nerve blocks may be considered for patients with suboptimal pain control.

Postherpetic Neuralgia
Postherpetic neuralgia, the most common complication of herpes zoster, is defined as pain in a dermatomal distribution that is sustained for at least 90 days after the rash. It occurs in approximately 20% of patients with herpes zoster and 80% of cases occur in patients 50 years or older. Pain is described as burning or electric shock–like and may be associated with allodynia or hyperalgesia. Postherpetic neuralgia is caused by nerve damage secondary to an inflammatory response induced by viral replication within a nerve. Risk factors include older age, severe prodrome or rash, severe acute zoster pain, ophthalmic involvement, immunosuppression, and chronic conditions such as diabetes mellitus and lupus. Pain from postherpetic neuralgia is often debilitating and affects physical functioning, psychological well-being, and quality of life. Pain-management strategies should focus on symptom control. Although some patients have complete resolution of symptoms at several years, others continue medications indefinitely (Table 2).

**Table 2. Pharmacologic Therapies for Postherpetic Neuralgia**

<table>
<thead>
<tr>
<th>Agent</th>
<th>Dosage (adult)</th>
<th>Adverse effects</th>
<th>Notes</th>
<th>Cost*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Topical treatments</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capsaicin 0.075% cream</td>
<td>Four applications per day</td>
<td>Erythema, pain on application, rash</td>
<td>Avoid contact with eyes and mucous membranes; 8% patch available for application by trained clinicians every three months</td>
<td>$18 for 2-oz tube (over the counter)</td>
</tr>
<tr>
<td>Lidocaine 5% patch</td>
<td>Up to three patches per day</td>
<td>Blisters, local erythema, rash</td>
<td>Avoid in patients with allergy to amide local anesthetics</td>
<td>$219 for 90 generic patches</td>
</tr>
<tr>
<td><strong>Systemic treatments</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>Initial dose of 10 to 25 mg orally at bedtime, then increase by 10 to 25 mg per week to target of 75 to 150 mg per day</td>
<td>Blurred vision, constipation, dry mouth, sedation, urinary retention, weight gain</td>
<td>Taper gradually when discontinuing therapy; use caution in older adults; avoid in patients with cardiac arrhythmias, glaucoma, seizure disorder, or suicide risk; avoid concomitant use of tramadol, selective serotonin reuptake inhibitors, and serotonin-norepinephrine reuptake inhibitors (risk of serotonin syndrome)</td>
<td>$4 for 30 75-mg generic tablets</td>
</tr>
<tr>
<td>Gabapentin (Neurontin)</td>
<td>300 to 600 mg orally three times per day</td>
<td>Dizziness, peripheral edema, sedation, weight gain</td>
<td>Taper dose over seven days when discontinuing therapy; dosing adjustment required for patients with creatinine clearance ≤ 60 mL per minute per 1.73 m² (1.00 mL per second per m²)</td>
<td>$13 for 90 300-mg generic capsules ($406 for brand name)</td>
</tr>
<tr>
<td>Pregabalin (Lyrica)</td>
<td>150 to 300 mg orally per day in two or three divided doses</td>
<td>Dizziness, peripheral edema, sedation, weight gain</td>
<td>Taper dose over seven days when discontinuing therapy; dosing adjustment required for patients with creatinine clearance ≤ 60 mL per minute per 1.73 m²</td>
<td>$395 for 60 75-mg brand name capsules (generic not available)</td>
</tr>
</tbody>
</table>


Information from references 11, 27, 36, and 37.
tiveness. Although one systematic review demonstrated improved pain, a Cochrane review of six randomized controlled trials (RCTs) concluded the evidence supporting its use is lacking.

Capsaicin is also an option for pain relief. A meta-analysis of four RCTs with 1,272 patients concluded that capsaicin 8% patches applied for 30 to 90 minutes provided greater pain relief than low-concentration topical capsaicin after 12 weeks (number needed to treat [NNT] = 7; 95% confidence interval [CI], 5 to 15). However, the 8% patch is irritating and likely to cause pain when applied. A trained clinician should pretreat the application site with topical anesthetic before affixing the patch. Lower-potency capsaicin cream (0.075%) has also been used to treat postherpetic neuralgia, although a Cochrane review concluded that there was insufficient evidence to recommend its use.

SYSTEMIC TREATMENTS

The anticonvulsants gabapentin (Neurontin) and pregabalin (Lyrica) are approved for treatment of postherpetic neuralgia. Several meta-analyses have shown that gabapentin (1,800 to 3,600 mg per day; NNT = 8; 95% CI, 5 to 14) and pregabalin (600 mg per day; NNT = 4; 95% CI, 3 to 9) were more effective than placebo in achieving 50% reduction in pain. Despite their effectiveness, the time needed to titrate these agents to an effective dose (up to 10 weeks) and their adverse effects (e.g., somnolence) may limit their use.

Tricyclic antidepressants are also effective in treating postherpetic neuralgia. A meta-analysis of four RCTs comparing amitriptyline, nortriptyline (Pamelor), and desipramine with placebo estimated an NNT of 3 (95% CI, 2 to 4) to achieve meaningful pain relief. A Cochrane review found no differences in pain relief among the tricyclic antidepressants after four weeks, but all were superior to placebo. Up to one-fourth of patients taking tricyclic antidepressants discontinue treatment because of adverse effects such as confusion, sedation, urinary retention, and cardiotoxicity.

Opioids are considered third-line treatment for postherpetic neuralgia. A Cochrane review concluded that the benefit of opioids for neuropathic pain is uncertain because of a lack of unbiased evidence. Two systematic reviews found that tramadol provided significant pain relief in patients with postherpetic neuralgia (NNT = 4 or 5).

**SORT: KEY RECOMMENDATIONS FOR PRACTICE**

<table>
<thead>
<tr>
<th>Clinical recommendation</th>
<th>Evidence rating</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Although herpes zoster typically is diagnosed clinically, if laboratory confirmation is needed, polymerase chain reaction testing of vesicle or other fluids is preferred for diagnosis because of its high sensitivity (95%) and specificity (100%).</td>
<td>C</td>
<td>7</td>
</tr>
<tr>
<td>Acyclovir, valacyclovir (Valtrex), and famciclovir are effective treatments for herpes zoster and ideally should be started within 72 hours of the appearance of the rash to decrease the duration of symptoms and severity of pain.</td>
<td>B</td>
<td>1, 2, 7, 14-16</td>
</tr>
<tr>
<td>Capsaicin 8% patches, applied for 30 to 90 minutes, provide effective pain relief for patients with postherpetic neuralgia.</td>
<td>A</td>
<td>40</td>
</tr>
<tr>
<td>Gabapentin (Neurontin) and pregabalin (Lyrica) can be used for treatment of postherpetic neuralgia.</td>
<td>A</td>
<td>42</td>
</tr>
<tr>
<td>Amitriptyline, nortriptyline (Pamelor), and desipramine can be used for pain relief in patients with postherpetic neuralgia (number needed to treat = 3; 95% confidence interval, 2 to 4).</td>
<td>A</td>
<td>26, 44</td>
</tr>
<tr>
<td>The varicella zoster virus vaccine (Zostavax) should be given to patients 60 years and older, but it is contraindicated in those who are immunosuppressed, have human immunodeficiency virus infection and CD4 lymphocyte counts less than 200 per mm³ (0.20 × 10⁹ per L), are undergoing cancer treatment, or who have cancer affecting the bones or lymphatic system.</td>
<td>A</td>
<td>48, 50, 51</td>
</tr>
</tbody>
</table>

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.
The potential harms of systemic therapies for postherpetic neuralgia should be considered before treating older patients or those with comorbidities. A thorough assessment, including a medication review and physical examination focusing on balance, gait, and orthostatic vital signs, will help minimize adverse effects of treatment and interactions between treatments and other medications. The American Geriatrics Society advocates initiating medications for persistent pain at low doses and titrating slowly.

Prevention
Herpes zoster and postherpetic neuralgia are vaccine preventable. The VZV vaccine (Zostavax) has been shown in clinical trials to decrease the incidence of herpes zoster and is approved for adults 50 years and older. The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices recommends vaccination for adults 60 years and older, regardless of whether they had naturally occurring varicella. The VZV vaccine is more effective in persons 60 to 69 years of age than in those 70 years and older, and it is more cost-effective to vaccinate those 60 years and older.

The VZV vaccine is contraindicated in immunosuppressed persons, those with human immunodeficiency virus infection and CD4 lymphocyte counts less than 200 per mm\(^3\) (0.20 × 10\(^9\) per L), patients undergoing cancer treatment, and those with cancer affecting the bones or lymphatic system. Vaccine effectiveness is 69% in the first year, but wanes to 4% in the eighth year; there are no recommendations for revaccinating persons who receive the vaccine at 60 years or older, and there are no recommendations for vaccinating persons who previously received the varicella vaccine.

Because some patients who are at high risk of herpes zoster cannot receive the live VZV vaccine, an adjuvant recombinant VZV vaccine has been developed. It has shown promise in clinical trials among persons 50 years and older who have no history of immunosuppression, but it is not yet approved by the U.S. Food and Drug Administration. The incidence of herpes zoster in those receiving the vaccine decreased by 96% (95% CI, 90% to 98%) compared with placebo. Like the live attenuated VZV vaccine, the recombinant vaccine is well tolerated; however, its effectiveness is not dependent on age, and it does not carry the risk of inducing herpes zoster.

The most effective way to prevent postherpetic neuralgia is to prevent herpes zoster. The Shingles Prevention Study found the live VZV vaccine to be 67% effective (95% CI, 51% to 96%) in preventing postherpetic neuralgia by decreasing the incidence of herpes zoster by 51% (95% CI, 44% to 58%). The protective effects of the vaccine last an average of at least three years, and inferred data indicate that it prevents herpes zoster for five years in patients 60 years and older. Patients who are vaccinated and then develop herpes zoster have decreased duration and severity of symptoms compared with those who received placebo. Among adults 65 years of age, the numbers needed to vaccinate to prevent one case of herpes zoster and one case of postherpetic neuralgia are 11 and 43, respectively.

Although the VZV vaccine is effective, it is underused, likely in part because of the cost. Although the vaccine is covered by Medicare Part D, when annual deductibles and copayments are factored in, the vaccine can be cost-prohibitive. In 2013, the VZV vaccination rate was only 24.2% among adults 60 years and older. White adults receive the vaccine at almost three times the rate of blacks and Hispanics. Patient education can increase vaccination rates by helping patients understand the benefits and ways in which patients may be able to work with insurance companies to find an affordable means of obtaining it.

This article updates previous articles on this topic by Fashner and Bell; Mounsey, et al.; and Stankus, et al.

Data Sources: We searched the Cochrane Database of Systematic Reviews, the National Guideline Clearinghouse, PubMed, and Essential Evidence Plus using the following key words: herpes zoster, varicella zoster virus, postherpetic neuralgia, and zoster vaccine. Search dates: October 2015 through March 2017.

Figure 1 courtesy of Leonard Sperling, MD, Colonel, U.S. Army (retired).
The views expressed in this article are the authors’ own and do not necessarily reflect the views of the U.S. Army, U.S. Navy, U.S. Air Force, the Department of Defense, or the U.S. government.

The Authors

AARON SAGUIL, MD, MPH, is an associate professor in the Department of Family Medicine at F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Md.

SHAWN KANE, MD, is an assistant professor in the Department of Family Medicine at F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences.

MICHAEL MERCADO, MD, is an assistant professor in the Department of Family Medicine at F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences.

REBECCA LAUTERS, MD, is chief resident in the Department of Family Medicine at Nellis Family Medicine Residency, Mike O’Callaghan Federal Medical Center, Nellis Air Force Base, Nev.

Address correspondence to Aaron Saguil, MD, MPH, 4301 Jones Bridge Rd., Bethesda, MD 20814 (e-mail: aaron.saguil@usuhs.edu). Reprints are not available from the authors.

REFERENCES